|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HD Preisler, A Raza and RA Larson
Department of Internal Medicine, University of Cincinnati, OH.
Ten patients with active acute myelogenous leukemia (AML) received either
13 cis retinoic acid (RA) + alpha interferon (IFN) or recombinant human
granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for 3 days.
Cell cycle measurements were performed before and at the conclusion of
administration of the bioactive agent(s). The proliferative rate of the
leukemia cells in vivo decreased in four of five patients receiving RA+IFN
whereas in one patient proliferation accelerated. The proliferative rate of
AML cells accelerated in three of the five patients who received rhGM-CSF
and slowed in two patients. These data show that while the proliferative
rate of AML cells can be altered in vivo, the effect produced by bioactive
agents may be the opposite of the desired effect. Furthermore, the studies
described here demonstrate the usefulness of marrow biopsies for measuring
the percent S-phase cells and the importance of measuring the duration of S
phase so that the effects of bioactive agents on the cell cycle time of the
leukemia cells can be determined.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1992 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
